Recent Data on Neoadjuvant Therapy in HR+/HER2- Breast Cancer
The expert panel reviews data updates on neoadjuvant therapy in HR+/HR2- early breast cancer and discusses the role of CDK4/6 inhibition in this setting.
Source: onclive.com
📰 Recent Data Updates News
Recent Data Updates News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Recent Data Updates. Real-time updates on events, politics, business and more.
Circulating Tumor DNA as a Prognostic Marker in HR+/HER2- Breast Cancer
A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.
Evolving Treatment Paradigms Recent Data Updates Prognostic Marker Hr Her2 Breast Cancer Cdk4 6 Inhibitors Penelope B
Source: onclive.com
Neoadjuvant Systemic Therapy for HER2+ eBC: Clinical Considerations and Evolving Modalities
Panelists expand upon the most important clinical factors that inform selection amongst available systemic therapy regimens in the neoadjuvant setting of HER2+ eBC, comment on the potential for treatment de-escalation in lower-risk patients, and discuss exciting treatments on the horizon.
Source: onclive.com
HER2+ Early Breast Cancer: Treatment Optimization and Review of Standard-of-Care Neoadjuvant Regimens
Heather McArthur, MD, and Debu Tripathy, MD, lead a discussion on risk stratification and optimizing treatment for HER2+ early breast cancer (eBC), followed by a review of standard-of-care systemic therapy regimens in the preoperative/neoadjuvant setting.
Heather Mcarthur Breast Cancer Recent Data Updates Key Advances Early Breast Cancer Treatment Optimization
Source: onclive.com